According to the official website of the China State Drug Administration the application for marketing authorization of Feisumei (benaglutide) injection for obesity or overweight indications declared by Benemae Pharmaceuticals/Renhui Biotech was approved for weight management of adults.
The first original new drug approved for weight loss indications in China, and the third GLP-1 weight loss drug approved globally after Danish diabetes care giant Novo Nordisk's (NOV: N) developed liraglutide and semaglutide drugs bring new treatment options for overweight and obese patients.
Benaglutide is a fully human GLP-1 receptor agonist independently developed by Renhui Biotechnology. Its amino acid sequence is 100% identical to the human natural GLP-1. It is characterized by a low incidence of antibodies, significant curative effect, and better safety.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze